N-Acetyl Peptides: What the Acetyl Group Actually Changes

Three pairs of products in our catalogue differ by two characters on the label: Semax and N-Acetyl Semax, Selank and N-Acetyl Selank, Epithalon and N-Acetyl Epithalon. In each pair the acetylated version costs more. The chemistry behind that is real and well understood. The claims usually attached to it are mostly not, and there is a separate trap in the paperwork that catches careful buyers: a certificate saying “acetate” is not telling you the peptide is acetylated.

This article explains what an N-terminal acetyl group is, what it is demonstrated to do in general, what is actually published on these three acetylated peptides specifically, and how a certificate proves which form is in the vial. It also corrects something we previously published ourselves.

What the acetyl group is

A peptide’s N-terminus normally carries a free alpha-amino group, which at physiological pH is protonated and so positively charged. N-terminal acetylation replaces one hydrogen on that amino group with an acetyl group, CH3CO. Unimod, the community reference for mass-spectrometry modifications, lists acetylation as accession 1 with composition H(2) C(2) O, a monoisotopic mass change of 42.010565 and an average mass change of 42.0367, and names “Any N-term” among its specified sites.

Two consequences follow directly. The first is the mass: every acetylated peptide is heavier than its plain counterpart by that same fixed amount, regardless of sequence. The second is the charge: the acetylated N-terminus cannot be protonated, so the molecule carries one less positive charge and its isoelectric point shifts. Work on chromatographic retention prediction for peptides with modified amino groups describes acetylation as removing that charge, in contrast to tags that relocate it.

Because the acetyl group also changes the local hydrophobicity, the acetylated and plain forms do not co-elute on reverse-phase HPLC. We are deliberately not telling you which one comes off the column first: the direction of the shift depends on the peptide and the method, and we could not verify a general rule for it. What you can rely on is that they separate.

Acetylation in biology, and an honest caveat

This is not an exotic laboratory trick. N-terminal acetylation is one of the most common protein modifications there is. A 2018 review in Experimental & Molecular Medicine describes N-terminal acetyltransferases catalysing “the attachment of an acetyl moiety from acetyl-CoA to the N-termini of the cellular proteins”, grouped into NatA through NatG complexes, with NatA to NatE “conserved from yeast to humans”. It happens co-translationally, as the protein emerges from the ribosome, and the review puts its reach at “approximately 50–80% of the cellular proteins in eukaryotes”.

Here is the caveat that most product copy omits, and it comes from the title of that same paper: the review is about the control of protein degradation by N-terminal acetylation and the N-end rule pathway. In other words, an acetylated N-terminus is itself a recognition signal that can route a protein towards destruction, through what the field calls the Ac/N-degron pathway. So “acetylation makes peptides more stable” is a defensible statement about resistance to a particular class of enzyme in a tube. It is not a general law of biology, and the same modification participates in a degradation system.

What blocking the N-terminus does

The mechanical argument is straightforward. Aminopeptidases are exopeptidases that chew a peptide from its N-terminal end, and they need a free alpha-amino group to recognise and attack. Cap that group and you remove the substrate for that whole class of enzyme.

The literature supports this at the level of a general principle. A 2022 paper in the International Journal of Peptide Research and Therapeutics states in its abstract that “N-terminus acetylation and C-terminus amidation can strongly protect peptides from proteolytic degradation”. A 2021 paper in the Journal of Peptide Science reports, for one specific antimicrobial peptide, that “N-terminal acetylation enhanced the stability against pH, plasma, and trypsin degradation” — a demonstrated result, though for a molecule unrelated to the three here.

What does not follow is a quantitative claim about Semax, Selank or Epithalon. We found no published figure for how much longer any of their acetylated forms survives, in what medium, against which enzyme. The aminopeptidase route is clearly a studied question for Semax analogues — a 2011 paper in the Russian Journal of Bioorganic Chemistry is titled as a study of exactly that — but we could retrieve only its citation, not its results, so we are not characterising what it found. Our guide to peptide stability and degradation covers the broader mechanisms.

Acetate is not N-acetyl

This is the single most useful thing in this article for anyone reading a certificate, and it catches experienced buyers.

The practical rule: an “N-Acetyl” product name is a claim about covalent structure, and the thing that substantiates it is a measured mass showing the 42 Da shift. Not the salt form, and not a retention time. Our article on net peptide content and TFA or acetate counter-ions covers how salts affect what you actually weigh out, and peptide sequence notation explains how Ac- and other end caps are written.

The three pairs, and what is published on each

Verified sequences first, because the acetylation question only makes sense against a known structure.

On Semax specifically, one point of precision that is widely got wrong, including in vendor datasheets. Semax is routinely described as ACTH(4-10) with a Pro-Gly-Pro extension. Reading the curated POMC sequence, UniProt P01189, corticotropin begins SYSMEHFRWG, which makes ACTH(4-10) equal to Met-Glu-His-Phe-Arg-Trp-Gly. Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The Arg-Trp-Gly is simply not there. The accurate description is that Semax is an analogue of the ACTH(4-10) region built from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro, and we have used that form here.

On the absorption claim: the idea that acetylation improves bioavailability or nasal absorption for these peptides is everywhere in product copy. We searched for published support and found none for any of the three. We are recording that the claim exists and that we could not substantiate it, which is different from saying it is false — but an unsubstantiated claim should not drive a purchasing decision.

And on activity: nothing we found establishes that acetylation preserves, increases or reduces what any of these three peptides does. The rodent BDNF data that circulates for Semax belongs to plain Semax. Our article on neurotrophic factors sets out exactly what that data shows and does not show, and Semax versus Selank compares the two unmodified peptides.

A correction to our own earlier article

In an earlier article on neurotrophic factors we stated that N-Acetyl Semax has no primary literature at all. That was wrong, and we are correcting it here rather than quietly leaving it.

At least one primary paper exists: Shevchenko and colleagues, “Stability of Semax acetyl to proteolysis in various biological media”, Doklady Biological Sciences, 2013, volume 449, pages 110 to 112. We verified the citation but could not retrieve the paper itself, so we are not characterising its findings — only recording that the work exists and concerns proteolytic stability rather than behavioural or neurotrophic outcomes.

The substance of the original point survives the correction, and it is worth restating precisely: the rodent BDNF and trkB data that people cite when discussing N-Acetyl Semax were generated with plain Semax. There is a small primary literature on the acetylated form, and it is about stability in a tube, not about what the molecule does in an animal.

What’s established and what isn’t

Sourcing either form in Canada

For these product pairs the documentation question is unusually specific: you are asking the certificate to prove a covalent modification, not just a purity level.

• Look for a measured mass that shows the 42 Da shift. That is what substantiates an “N-Acetyl” label. Our mass spectrum guide covers reading the result.
• Read the salt form separately from the modification. “Monoacetate” or “trifluoroacetate” describes a counter-ion, not an acetylated N-terminus.
• Do not let the plain peptide’s literature travel to the acetylated one, or the reverse. They are different molecules with different published records.
• Match the batch number on the certificate to the one on your vial, and see the COA guide for what else a useful report contains.

Research peptides with published test reports

Both forms of Semax and Selank are in the catalogue as separate products. Janoshik Analytical certificates for most research products are listed by batch on our Lab Testing page; the rest are available on request.

SemaxThe unmodified heptapeptide, Met-Glu-His-Phe-Pro-Gly-ProView product N-Acetyl SemaxThe acetylated form, subject of a 2013 stability paperView product SelankTuftsin with a C-terminal Pro-Gly-Pro extensionView product N-Acetyl SelankThe acetylated form; no published study locatedView product

Frequently asked questions